Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma

Chen, 2016, Cancer statistics in China, 2015, CA Cancer J Clin, 66, 115, 10.3322/caac.21338 Forner, 2018, Hepatocellular carcinoma, Lancet, 391, 1301, 10.1016/S0140-6736(18)30010-2 Villanueva, 2019, Hepatocellular carcinoma, N Engl J Med, 380, 1450, 10.1056/NEJMra1713263 Abou-Alfa, 2010, Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial, JAMA, 304, 2154, 10.1001/jama.2010.1672 Qin, 2013, Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia, J Clin Oncol, 31, 3501, 10.1200/JCO.2012.44.5643 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1 Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9 Abou-Alfa, 2018, Cabozantinib in patients with advanced and progressing hepatocellular carcinoma, N Engl J Med, 379, 54, 10.1056/NEJMoa1717002 Zhu, 2015, Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 16, 859, 10.1016/S1470-2045(15)00050-9 Rimassa, 2019, Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma, Cancer Treat Rev, 77, 20, 10.1016/j.ctrv.2019.05.004 Zhai, 2013, Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma, World J Hepatol, 5, 345, 10.4254/wjh.v5.i7.345 Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745 Eslam, 2020, MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease, Gastroenterology, 158, 1999, 10.1053/j.gastro.2019.11.312 Xiong, 2020, hnRNPU/TrkB defines a chromatin accessibility checkpoint for liver injury and nonalcoholic steatohepatitis pathogenesis, Hepatology, 71, 1228, 10.1002/hep.30921 Degasperi, 2016, Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease, Lancet Gastroenterol Hepatol, 1, 156, 10.1016/S2468-1253(16)30018-8 Kanwal, 2016, Trends in the burden of nonalcoholic fatty liver disease in a United States Cohort of Veterans, Clin Gastroenterol Hepatol, 14, 301, 10.1016/j.cgh.2015.08.010 El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061 Morgan, 2004, Alcohol and hepatocellular carcinoma, Gastroenterology, 127, S87, 10.1053/j.gastro.2004.09.020 Gingold, 2018, Genomic profiling and metabolic homeostasis in primary liver cancers, Trends Mol Med, 24, 395, 10.1016/j.molmed.2018.02.006 Pavlova, 2016, The emerging hallmarks of cancer metabolism, Cell Metab, 23, 27, 10.1016/j.cmet.2015.12.006 Hay, 2016, Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?., Nat Rev Cancer, 16, 635, 10.1038/nrc.2016.77 Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 Guzman, 2015, Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma, Dig Dis Sci, 60, 420, 10.1007/s10620-014-3364-3 Mazurek, 2005, Pyruvate kinase type M2 and its role in tumor growth and spreading, Semin Cancer Biol, 15, 300, 10.1016/j.semcancer.2005.04.009 Tong, 2009, The molecular determinants of de novo nucleotide biosynthesis in cancer cells, Curr Opin Genet Dev, 19, 32, 10.1016/j.gde.2009.01.002 Mossenta, 2020, Glucose metabolism and oxidative stress in hepatocellular carcinoma: role and possible implications in novel therapeutic strategies, Cancers (Basel), 12, 1668, 10.3390/cancers12061668 Liu, 2017, Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase, Hepatology, 66, 631, 10.1002/hep.29202 Guo, 2019, NRF2 SUMOylation promotes de novo serine synthesis and maintains HCC tumorigenesis, Cancer Lett, 466, 39, 10.1016/j.canlet.2019.09.010 Fruman, 2014, PI3K and cancer: lessons, challenges and opportunities, Nat Rev Drug Discov, 13, 140, 10.1038/nrd4204 Colell, 2009, Novel roles for GAPDH in cell death and carcinogenesis, Cell Death Differ, 16, 1573, 10.1038/cdd.2009.137 Gong, 2019, Nuclear GAPDH is vital for hypoxia-induced hepatic stellate cell apoptosis and is indicative of aggressive hepatocellular carcinoma behavior, Cancer Manag Res, 11, 4947, 10.2147/CMAR.S202268 Semenza, 1994, Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1, J Biol Chem, 269, 23757, 10.1016/S0021-9258(17)31580-6 Sharp, 2004, HIF1 and oxygen sensing in the brain, Nat Rev Neurosci, 5, 437, 10.1038/nrn1408 Kawai, 2017, Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis, Int J Oncol, 50, 525, 10.3892/ijo.2016.3814 Jiao, 2018, Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2), Autophagy, 14, 671, 10.1080/15548627.2017.1381804 Liu, 2015, PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma, Oncotarget, 6, 846, 10.18632/oncotarget.2749 Luo, 2011, Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1, Cell, 145, 732, 10.1016/j.cell.2011.03.054 Dey, 2019, PKM2 knockdown induces autophagic cell death via AKT/mTOR pathway in human prostate cancer cells, Cell Physiol Biochem, 52, 1535 Cao, 2020, Long noncoding RNA MSC-AS1 promotes hepatocellular carcinoma oncogenesis via inducing the expression of phosphoglycerate kinase 1, Cancer Med, 9, 5174, 10.1002/cam4.3080 Chen, 2019, MicroRNA-450b-3p inhibits cell growth by targeting phosphoglycerate kinase 1 in hepatocellular carcinoma, J Cell Biochem, 120, 18805, 10.1002/jcb.29196 Zhao, 2020, HCAR1/MCT1 regulates tumor ferroptosis through the lactate-mediated AMPK–SCD1 activity and its therapeutic implications, Cell Rep, 33, 108487, 10.1016/j.celrep.2020.108487 Zhang, 2019, Metabolic regulation of gene expression by histone lactylation, Nature, 574, 575, 10.1038/s41586-019-1678-1 Wu, 2019, Quercetin inhibits the proliferation of glycolysis-addicted HCC cells by reducing hexokinase 2 and Akt–mTOR pathway, Molecules, 24, 1993, 10.3390/molecules24101993 Li, 2020, Novel mitochondrion-targeting copper(II) complex induces HK2 malfunction and inhibits glycolysis via Drp1-mediating mitophagy in HCC, J Cell Mol Med, 24, 3091, 10.1111/jcmm.14971 Riganti, 2012, The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate, Free Radic Biol Med, 53, 421, 10.1016/j.freeradbiomed.2012.05.006 Hong, 2014, PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis, Gut, 63, 1635, 10.1136/gutjnl-2013-305302 Qin, 2019, Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner, J Exp Clin Cancer Res, 38, 154, 10.1186/s13046-019-1131-1 Sukhatme, 2012, Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence, FEBS Lett, 586, 2389, 10.1016/j.febslet.2012.05.052 Lu, 2018, Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial–mesenchymal transition, Acta Biochim Biophys Sin, 50, 370, 10.1093/abbs/gmy009 Xu, 2016, Transketolase counteracts oxidative stress to drive cancer development, Proc Natl Acad Sci U S A, 113, E725, 10.1073/pnas.1508779113 Langbein, 2006, Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted, Br J Cancer, 94, 578, 10.1038/sj.bjc.6602962 Zhang, 2018, Unraveling the regulation of hepatic gluconeogenesis, Front Endocrinol (Lausanne), 9, 802, 10.3389/fendo.2018.00802 Li, 2020, FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome, Nat Cell Biol, 22, 728, 10.1038/s41556-020-0511-2 Tuo, 2018, PCK1 downregulation promotes TXNRD1 expression and hepatoma cell growth via the Nrf2/Keap1 pathway, Front Oncol, 8, 611, 10.3389/fonc.2018.00611 Cho, 2017, Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia, PLoS Genet, 13, 10.1371/journal.pgen.1006819 Cho, 2018, Sirtuin signaling controls mitochondrial function in glycogen storage disease type Ia, J Inherit Metab Dis, 41, 997, 10.1007/s10545-018-0192-1 Cho, 2018, Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia, Biochem Biophys Res Commun, 498, 925, 10.1016/j.bbrc.2018.03.083 Montal, 2015, PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth, Mol Cell, 60, 571, 10.1016/j.molcel.2015.09.025 Liu, 2018, Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma, Oncogene, 37, 1637, 10.1038/s41388-017-0070-6 Xu, 2020, The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis, Nature, 580, 530, 10.1038/s41586-020-2183-2 Hui, 2017, Glucose feeds the TCA cycle via circulating lactate, Nature, 551, 115, 10.1038/nature24057 Owen, 2002, The key role of anaplerosis and cataplerosis for citric acid cycle function, J Biol Chem, 277, 30409, 10.1074/jbc.R200006200 Wattanavanitchakorn, 2019, Differential contribution of pyruvate carboxylation to anaplerosis and cataplerosis during non-gluconeogenic and gluconeogenic conditions in HepG2 cells, Arch Biochem Biophys, 676, 108124, 10.1016/j.abb.2019.108124 Sun, 2019, Overexpression of pyruvate dehydrogenase E1α subunit inhibits Warburg effect and induces cell apoptosis through mitochondria-mediated pathway in hepatocellular carcinoma, Oncol Res, 27, 407, 10.3727/096504018X15180451872087 Tian, 2015, Isocitrate dehydrogenase 2 suppresses the invasion of hepatocellular carcinoma cells via matrix metalloproteinase 9, Cell Physiol Biochem, 37, 2405, 10.1159/000438593 Zhang, 2014, Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients, Med Oncol, 31, 278, 10.1007/s12032-014-0278-z Su, 2016, Expression of malic enzymes in sebaceous lesions, Am J Dermatopath, 38, 580, 10.1097/DAD.0000000000000451 Wen, 2015, Malic enzyme 1 induces epithelial–mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma, Tumour Biol, 36, 6211, 10.1007/s13277-015-3306-5 Shao, 2020, Cytosolic ME1 integrated with mitochondrial IDH2 supports tumor growth and metastasis, Redox Biol, 36, 101685, 10.1016/j.redox.2020.101685 Grohmann, 2018, Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC, Cell, 175, 1289, 10.1016/j.cell.2018.09.053 Wang, 2016, Dysregulated fatty acid metabolism in hepatocellular carcinoma, Hepat Oncol, 3, 241, 10.2217/hep-2016-0012 Riscal, 2019, Even cancer cells watch their cholesterol!., Mol Cell, 76, 220, 10.1016/j.molcel.2019.09.008 Attane, 2020, Drilling for oil: tumor-surrounding adipocytes fueling cancer, Trends Cancer, 6, 593, 10.1016/j.trecan.2020.03.001 Nath, 2015, Elevated free fatty acid uptake via CD36 promotes epithelial–mesenchymal transition in hepatocellular carcinoma, Sci Rep, 5, 14752, 10.1038/srep14752 Ku, 2016, Liver fatty acid-binding protein (l-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma, Oncotarget, 7, 18229, 10.18632/oncotarget.7571 Ohata, 2017, Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial–mesenchymal transition, Cancer Med, 6, 1049, 10.1002/cam4.1020 Seo, 2020, Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells, Commun Biol, 3, 638, 10.1038/s42003-020-01367-5 Jeong, 2012, Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma, Oncol Rep, 28, 1283, 10.3892/or.2012.1922 Mead, 2002, Lipoprotein lipase: structure, function, regulation, and role in disease, J Mol Med (Berl), 80, 753, 10.1007/s00109-002-0384-9 Wu, 2020, Tumor suppressor ZHX2 inhibits NAFLD-HCC progression via blocking LPL-mediated lipid uptake, Cell Death Differ, 27, 1693, 10.1038/s41418-019-0453-z Icard, 2020, ATP citrate lyase: a central metabolic enzyme in cancer, Cancer Lett, 471, 125, 10.1016/j.canlet.2019.12.010 Fullerton, 2013, Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin, Nat Med, 19, 1649, 10.1038/nm.3372 Lally, 2019, Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma, Cell Metab, 29, 174, 10.1016/j.cmet.2018.08.020 Che, 2019, Pathogenetic, prognostic, and therapeutic role of fatty acid synthase in human hepatocellular carcinoma, Front Oncol, 9, 1412, 10.3389/fonc.2019.01412 Ntambi, 2003, Recent insights into stearoyl-CoA desaturase-1, Curr Opin Lipidol, 14, 255, 10.1097/00041433-200306000-00005 Qiang, 2015, Hepatic SirT1-dependent gain of function of stearoyl-CoA desaturase-1 conveys dysmetabolic and tumor progression functions, Cell Rep, 11, 1797, 10.1016/j.celrep.2015.05.025 Lai, 2017, Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a Wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6, Gastroenterology, 152, 1477, 10.1053/j.gastro.2017.01.021 Bhushan, 2019, Pharmacologic inhibition of epidermal growth factor receptor suppresses nonalcoholic fatty liver disease in a murine fast-food diet model, Hepatology, 70, 1546, 10.1002/hep.30696 Huang, 2015, SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway, Cancer Lett, 358, 180, 10.1016/j.canlet.2014.12.036 Ma, 2017, Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation, J Hepatol, 67, 979, 10.1016/j.jhep.2017.06.015 Chen, 2020, ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis, Oncogenesis, 9, 42, 10.1038/s41389-020-0226-z Li, 2014, SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma, Int J Mol Sci, 15, 7124, 10.3390/ijms15057124 Surugiu-Wärnmark, 2005, Selection of DNA aptamers against rat liver X receptors, Biochem Biophys Res Commun, 332, 512, 10.1016/j.bbrc.2005.04.147 Xiong, 2019, TO901317 inhibits the development of hepatocellular carcinoma by LXRα/Glut1 decreasing glycometabolism, Am J Physiol Gastrointest Liver Physiol, 316, G598, 10.1152/ajpgi.00061.2018 Ahn, 2014, Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease, Dig Dis Sci, 59, 2975, 10.1007/s10620-014-3289-x Shimizu, 2020, Oxidative stress and liver X receptor agonist induce hepatocellular carcinoma in non-alcoholic steatohepatitis model, J Gastroenterol Hepatol, 36, 800, 10.1111/jgh.15239 Lu, 2019, Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2, Mol Carcinog, 58, 749, 10.1002/mc.22967 Wang, 2016, Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients, Hepatology, 63, 1272, 10.1002/hep.28415 Zhang, 2015, HIF-1 suppresses lipid catabolism to promote cancer progression, Mol Cell Oncol, 2 Huang, 2014, HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression, Cell Rep, 8, 1930, 10.1016/j.celrep.2014.08.028 Bolsoni-Lopes, 2015, Lipolysis and lipases in white adipose tissue—an update, Arch Endocrinol Metab, 59, 335, 10.1590/2359-3997000000067 Zhu, 2016, Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-κB-mediated epithelial–mesenchymal transition, J Hematol Oncol, 9, 127, 10.1186/s13045-016-0361-3 Liu, 2018, Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation, Mol Cancer, 17, 90, 10.1186/s12943-018-0838-5 Che, 2020, Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans, Gut, 69, 177, 10.1136/gutjnl-2018-317581 Mullen, 2016, The interplay between cell signalling and the mevalonate pathway in cancer, Nat Rev Cancer, 16, 718, 10.1038/nrc.2016.76 Montero, 2008, Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma, Cancer Res, 68, 5246, 10.1158/0008-5472.CAN-07-6161 Desvergne, 1999, Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr Rev, 20, 649 Kim, 2019, Keratin 23 is a peroxisome proliferator-activated receptor alpha-dependent, MYC-amplified oncogene that promotes hepatocyte proliferation, Hepatology, 70, 154, 10.1002/hep.30530 Jarrar, 2019, Molecular functionality of cytochrome P450 4 (CYP4) genetic polymorphisms and their clinical implications, Int J Mol Sci, 20, 4274, 10.3390/ijms20174274 Hardwick, 2008, Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases, Biochem Pharmacol, 75, 2263, 10.1016/j.bcp.2008.03.004 Rieger, 2004, Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma, Cancer Res, 64, 2357, 10.1158/0008-5472.CAN-03-0849 Yu, 2012, Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer, Toxicol Appl Pharmacol, 264, 73, 10.1016/j.taap.2012.07.019 Zheng, 2014, Pseudogene CYP4Z2P 3′UTR promotes angiogenesis in breast cancer, Biochem Biophys Res Commun, 453, 545, 10.1016/j.bbrc.2014.09.112 Zheng, 2019, Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells, J Hematol Oncol, 12, 23, 10.1186/s13045-019-0697-6 Zhang, 2017, Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine, EMBO J, 36, 1302, 10.15252/embj.201696151 Bhutia, 2016, Glutamine transporters in mammalian cells and their functions in physiology and cancer, Biochim Biophys Acta, 1863, 2531, 10.1016/j.bbamcr.2015.12.017 Yang, 2017, Glutaminolysis: a hallmark of cancer metabolism, Annu Rev Biomed Eng, 19, 163, 10.1146/annurev-bioeng-071516-044546 Xi, 2019, GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3beta/Cyclin D1 pathway, Exp Cell Res, 381, 1, 10.1016/j.yexcr.2019.04.005 Li, 2019, Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway, EBioMedicine, 39, 239, 10.1016/j.ebiom.2018.11.063 Suzuki, 2010, Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species, Proc Natl Acad Sci U S A, 107, 7461, 10.1073/pnas.1002459107 Du, 2020, Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression, Cell Mol Gastroenterol Hepatol, 10, 1, 10.1016/j.jcmgh.2019.12.006 Zhang, 2019, The SLC transporter in nutrient and metabolic sensing, regulation, and drug development, J Mol Cell Biol, 11, 1, 10.1093/jmcb/mjy052 Scalise, 2018, The human SLC1A5 (ASCT2) amino acid transporter: from function to structure and role in cell biology, Front Cell Dev Biol, 6, 96, 10.3389/fcell.2018.00096 Sun, 2016, GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma, PLoS One, 11, 10.1371/journal.pone.0168907 Bungard, 2004, Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter, Biochem J, 382, 27, 10.1042/BJ20040487 Scalise, 2018, The Human SLC7A5 (LAT1): the intriguing histidine/large neutral amino acid transporter and its relevance to human health, Front Chem, 6, 243, 10.3389/fchem.2018.00243 Ohkame, 2001, Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models, J Surg Oncol, 78, 265, 10.1002/jso.1165 Park, 2016, Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma, Hepatology, 63, 159, 10.1002/hep.28223 Janpipatkul, 2014, Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration, Cell Signal, 26, 1668, 10.1016/j.cellsig.2014.04.002 Li, 2013, The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma, Tumour Biol, 34, 2977, 10.1007/s13277-013-0861-5 Yan, 2019, Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex, Nature, 568, 127, 10.1038/s41586-019-1011-z Liu, 2020, LncRNA TMPO-AS1 aggravates the development of hepatocellular carcinoma via miR-429/GOT1 axis, Am J Med Sci, 360, 711, 10.1016/j.amjms.2020.08.010 Liu, 2019, Targeting the untargetable KRAS in cancer therapy, Acta Pharm Sin B, 9, 871, 10.1016/j.apsb.2019.03.002 Martinez, 2010, Genetic, structural and biochemical basis of carbamoyl phosphate synthetase 1 deficiency, Mol Genet Metab, 101, 311, 10.1016/j.ymgme.2010.08.002 2017, Comprehensive and integrative genomic characterization of hepatocellular carcinoma, Cell, 169, 1327, 10.1016/j.cell.2017.05.046 Yang, 2016, Studies on the biological functions of CPS1 in AFB1 induced hepatocarcinogenesis, Gene, 591, 255, 10.1016/j.gene.2016.07.031 Phillips, 2013, Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges, Cancer Res Treat, 45, 251, 10.4143/crt.2013.45.4.251 Tao, 2019, Argininosuccinate synthase 1 suppresses cancer cell invasion by inhibiting STAT3 pathway in hepatocellular carcinoma, Acta Biochim Biophys Sin (Shanghai), 51, 263, 10.1093/abbs/gmz005 You, 2018, The oncogenic role of ARG1 in progression and metastasis of hepatocellular carcinoma, Biomed Res Int, 2018, 2109865, 10.1155/2018/2109865 Bartlett, 2018, Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma, Pediatr Blood Cancer, 65, 10.1002/pbc.27392 He, 2019, Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma, Oncol Lett, 17, 5030 Lee, 2018, Cancer metabolism as a mechanism of treatment resistance and potential therapeutic target in hepatocellular carcinoma, Yonsei Med J, 59, 1143, 10.3349/ymj.2018.59.10.1143 Tomizawa, 2017, 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells, Oncol Lett, 13, 800, 10.3892/ol.2016.5510 Wang, 2019, The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells, Onco Targets Ther, 12, 5359, 10.2147/OTT.S212465 Sun, 2020, 3-Bromopyruvate regulates the status of glycolysis and BCNU sensitivity in human hepatocellular carcinoma cells, Biochem Pharmacol, 177, 113988, 10.1016/j.bcp.2020.113988 Pereira da Silva, 2009, Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate, Biochem J, 417, 717, 10.1042/BJ20080805 Yadav, 2017, Antitumor and chemosensitizing action of 3-bromopyruvate: implication of deregulated metabolism, Chem Biol Interact, 270, 73, 10.1016/j.cbi.2017.04.015 Ganapathy-Kanniappan, 2009, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death, Anticancer Res, 29, 4909 Liberti, 2017, A predictive model for selective targeting of the Warburg effect through GAPDH inhibition with a natural product, Cell Metab, 26, 648, 10.1016/j.cmet.2017.08.017 He, 2019, PGK1-mediated cancer progression and drug resistance, Am J Cancer Res, 9, 2280 Wang, 2020, Identification of a novel non-ATP-competitive protein kinase inhibitor of PGK1 from marine nature products, Biochem Pharmacol, 183, 114343, 10.1016/j.bcp.2020.114343 Wang, 2020, Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52, Acta Pharmacol Sin, 42, 633, 10.1038/s41401-020-0465-8 Hitosugi, 2012, Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth, Cancer Cell, 22, 585, 10.1016/j.ccr.2012.09.020 Xu, 2017, Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2, J Exp Clin Cancer Res, 36, 44, 10.1186/s13046-017-0514-4 Li, 2017, Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice, Oncotarget, 8, 45965, 10.18632/oncotarget.17469 Kim, 2017, Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells, J Transl Med, 15, 123, 10.1186/s12967-017-1223-7 Tang, 2018, Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/STAT3/cyclin D1 signal pathway, Life Sci, 204, 71, 10.1016/j.lfs.2018.05.012 Liu, 2020, Experimental study of hepatocellular carcinoma treatment by shikonin through regulating PKM2, J Hepatocell Carcino, 7, 19, 10.2147/JHC.S237614 Li, 2017, Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death, Br J Cancer, 117, 1518, 10.1038/bjc.2017.323 Xing, 2018, Anti-cancer effects of emodin on HepG2 cells as revealed by 1H NMR based metabolic profiling, J Proteome Res, 17, 1943, 10.1021/acs.jproteome.8b00029 Wei, 2019, DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK/mTOR signaling pathway, Phytomedicine, 54, 120, 10.1016/j.phymed.2018.09.003 Yang, 2017, Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression, Sci Rep, 7, 43864, 10.1038/srep43864 Pan, 2013, Suppression of gluconeogenic gene expression by LSD1-mediated histone demethylation, PLoS One, 8 Jin, 2017, MAGE–TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation, Oncogenesis, 6, 312, 10.1038/oncsis.2017.21 Schmidt Dawn, 2007, trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1, Biochemistry, 46, 4408, 10.1021/bi0618621 Roberti, 2019, Epigenetics in cancer therapy and nanomedicine, Clin Epigenetics, 11, 81, 10.1186/s13148-019-0675-4 Kim, 2012, An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma, Invest New Drugs, 30, 387, 10.1007/s10637-010-9532-1 Ma, 2013, Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma, Nat Commun, 4, 2508, 10.1038/ncomms3508 Abramson, 2011, The lipogenesis pathway as a cancer target, J Med Chem, 54, 5615, 10.1021/jm2005805 Wei, 2018, Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors, Bioorgan Med Chem, 26, 3866, 10.1016/j.bmc.2018.03.014 Wei, 2016, Combination therapy with a liver selective acetyl-CoA carboxylase inhibitor ND-654 and sorafenib improves efficacy in the treatment of cirrhotic rats with hepatocellular carcinoma, Cancer Res, 76, 3781, 10.1158/1538-7445.AM2016-3781 Zhou, 2003, Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells, Cancer Res, 63, 7330 Flavin, 2010, Fatty acid synthase as a potential therapeutic target in cancer, Future Oncol, 6, 551, 10.2217/fon.10.11 Falchook, 2017, Abstract CT153: first in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640, Cancer Res, 77, CT153, 10.1158/1538-7445.AM2017-CT153 Duke, 2017, Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH, J Hepatol, 66, S99, 10.1016/S0168-8278(17)30460-9 Gutierrez, 2014, Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus, Arterioscler Thromb Vasc Biol, 34, 676, 10.1161/ATVBAHA.113.302677 Ray, 2019, Safety and efficacy of bempedoic acid to reduce LDL cholesterol, N Engl J Med, 380, 1022, 10.1056/NEJMoa1803917 Hatzivassiliou, 2005, ATP citrate lyase inhibition can suppress tumor cell growth, Cancer Cell, 8, 311, 10.1016/j.ccr.2005.09.008 Gao, 2014, Inactivation of ATP citrate lyase by cucurbitacin B: a bioactive compound from cucumber, inhibits prostate cancer growth, Cancer Lett, 349, 15, 10.1016/j.canlet.2014.03.015 Choi, 2018, Targeting glutamine metabolism for cancer treatment, Biomol Ther (Seoul), 26, 19, 10.4062/biomolther.2017.178 Chen, 2019, Novel 1,3,4-selenadiazole-containing kidney-type glutaminase inhibitors showed improved cellular uptake and antitumor activity, J Med Chem, 62, 589, 10.1021/acs.jmedchem.8b01198 Shukla, 2012, Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors, J Med Chem, 55, 10551, 10.1021/jm301191p Gross, 2014, Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer, Mol Cancer Ther, 13, 890, 10.1158/1535-7163.MCT-13-0870 Schulte, 2018, Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models, Nat Med, 24, 194, 10.1038/nm.4464 Jin, 2020, A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer, Elife, 9, 10.7554/eLife.56749 Wang, 2019, Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer, Phytomedicine, 57, 117, 10.1016/j.phymed.2018.12.011 Zhang, 2019, Berberine inhibits growth of liver cancer cells by suppressing glutamine uptake, Onco Targets Ther, 12, 11751, 10.2147/OTT.S235667 Dhillon, 2018, Ivosidenib: first global approval, Drugs, 78, 1509, 10.1007/s40265-018-0978-3 Caravella, 2020, Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor, J Med Chem, 63, 1612, 10.1021/acs.jmedchem.9b01423 Guri, 2017, mTORC2 promotes tumorigenesis via lipid synthesis, Cancer Cell, 32, 807, 10.1016/j.ccell.2017.11.011 Liu, 2008, A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction, Mol Cancer Ther, 7, 263, 10.1158/1535-7163.MCT-07-0445 Menendez, 2005, Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene, Ann Oncol, 16, 1253, 10.1093/annonc/mdi239 Buckley, 2017, Fatty acid synthase—modern tumor cell biology insights into a classical oncology target, Pharmacol Therapeut, 177, 23, 10.1016/j.pharmthera.2017.02.021 Menendez, 2017, Fatty acid synthase (FASN) as a therapeutic target in breast cancer, Expert Opin Ther Tar, 21, 1001, 10.1080/14728222.2017.1381087 Zaytseva, 2018, Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer, Oncotarget, 9, 24787, 10.18632/oncotarget.25361 Thupari, 2002, C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity, Proc Natl Acad Sci U S A, 99, 9498, 10.1073/pnas.132128899 Graf, 2008, Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma, Digestion, 78, 34, 10.1159/000156702 Okano, 2020, First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors, Invest New Drugs, 38, 1495, 10.1007/s10637-020-00924-3 Sachs, 2017, Encouraging new uses for old drugs, JAMA, 318, 2421, 10.1001/jama.2017.17535 Pantziarka, 2018, New uses for old drugs, BMJ, 361 DeWaal, 2018, Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin, Nat Commun, 9, 446, 10.1038/s41467-017-02733-4 Hu, 2019, Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1alpha/PFKFB3/PFK1 pathway, Life Sci, 239, 116966, 10.1016/j.lfs.2019.116966 Kaji, 2018, Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake, Int J Cancer, 142, 1712, 10.1002/ijc.31193 Shiba, 2018, Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH, Sci Rep, 8, 2362, 10.1038/s41598-018-19658-7 Chen, 2017, Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer, Mol Cancer, 16, 131, 10.1186/s12943-017-0701-0 Bai, 2018, Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism, Oncogene, 37, 5666, 10.1038/s41388-018-0360-7 Liu, 2016, Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers, Cell Metab, 24, 728, 10.1016/j.cmet.2016.09.005 Dowling, 2007, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells, Cancer Res, 67, 10804, 10.1158/0008-5472.CAN-07-2310 Shaw, 2004, The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress, Proc Natl Acad Sci U S A, 101, 3329, 10.1073/pnas.0308061100 Watson, 2014, Type 2 diabetes as a redox disease, Lancet, 383, 841, 10.1016/S0140-6736(13)62365-X Silvestri, 2015, Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions, PLoS One, 10, 10.1371/journal.pone.0136250 Camacho, 2015, Metformin in breast cancer—an evolving mystery, Breast Cancer Res, 17, 88, 10.1186/s13058-015-0598-8 Chan, 2017, Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection, Liver Int, 37, 434, 10.1111/liv.13280 Scafoglio, 2015, Functional expression of sodium–glucose transporters in cancer, Proc Natl Acad Sci U S A, 112, E4111, 10.1073/pnas.1511698112 Amann, 2009, GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis, Am J Pathol, 174, 1544, 10.2353/ajpath.2009.080596 Obara, 2017, Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice, Oncotarget, 8, 58353, 10.18632/oncotarget.16874 Lehmann, 2016, Intestinal SGLT1 in metabolic health and disease, Am J Physiol Gastrointest Liver Physiol, 310, G887, 10.1152/ajpgi.00068.2016 Liu, 2019, Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP–AMPK–mTOR–SREBP1 signaling pathway, FASEB J, 33, 10089, 10.1096/fj.201802619RR Xu, 2021, UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1beta in hepatocellular carcinoma, Signal Transduct Target Ther, 6, 190, 10.1038/s41392-021-00594-4 Febbraio, 2019, Preclinical models for studying NASH-driven HCC: how useful are they?., Cell Metab, 29, 18, 10.1016/j.cmet.2018.10.012 Satriano, 2019, Metabolic rearrangements in primary liver cancers: cause and consequences, Nat Rev Gastroenterol Hepatol, 16, 748, 10.1038/s41575-019-0217-8 Jiang, 2011, p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase, Nat Cell Biol, 13, 310, 10.1038/ncb2172 Sun, 2015, cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions, Cell Res, 25, 429, 10.1038/cr.2015.33 Nuciforo, 2018, Organoid models of human liver cancers derived from tumor needle biopsies, Cell Rep, 24, 1363, 10.1016/j.celrep.2018.07.001